Nanoparticle technology demonstrates selective destruction of leukemia cancer cells
A research team, affiliated with UNIST has developed nanoparticles that effectively treat acute myeloid leukemia (AML), ...
Johnson & Johnson treatment of acute myeloid leukemia granted orphan status
The FDA granted orphan designation to Janssen Research & Development’s bleximenib as a treatment of acute myeloid leukemia, according ...
The American Journal of Managed Care1d
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML ...
The American Journal of Managed Care6d
Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML
Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...